nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP2C8—Vismodegib—skin cancer	0.115	0.197	CbGbCtD
Loperamide—ABCB1—Vismodegib—skin cancer	0.0777	0.133	CbGbCtD
Loperamide—CYP3A4—Imiquimod—skin cancer	0.0672	0.115	CbGbCtD
Loperamide—CYP3A4—Temozolomide—skin cancer	0.0672	0.115	CbGbCtD
Loperamide—CYP2D6—Vemurafenib—skin cancer	0.0579	0.0992	CbGbCtD
Loperamide—CYP3A4—Vismodegib—skin cancer	0.0466	0.0798	CbGbCtD
Loperamide—ABCB1—Dactinomycin—skin cancer	0.0408	0.07	CbGbCtD
Loperamide—CYP2C8—Fluorouracil—skin cancer	0.0408	0.0699	CbGbCtD
Loperamide—CYP3A4—Vemurafenib—skin cancer	0.0368	0.0631	CbGbCtD
Loperamide—ABCB1—Docetaxel—skin cancer	0.0211	0.0361	CbGbCtD
Loperamide—POMC—skin epidermis—skin cancer	0.0128	0.0923	CbGeAlD
Loperamide—CYP3A4—Docetaxel—skin cancer	0.0126	0.0216	CbGbCtD
Loperamide—POMC—nerve—skin cancer	0.0109	0.0787	CbGeAlD
Loperamide—CACNA1A—nerve—skin cancer	0.0104	0.0751	CbGeAlD
Loperamide—POMC—blood vessel—skin cancer	0.00857	0.0618	CbGeAlD
Loperamide—POMC—neck—skin cancer	0.00613	0.0442	CbGeAlD
Loperamide—CALM2—ear—skin cancer	0.00473	0.0341	CbGeAlD
Loperamide—CALM1—ear—skin cancer	0.00471	0.034	CbGeAlD
Loperamide—POMC—connective tissue—skin cancer	0.00439	0.0317	CbGeAlD
Loperamide—OPRM1—nerve—skin cancer	0.00411	0.0296	CbGeAlD
Loperamide—POMC—skin of body—skin cancer	0.00397	0.0286	CbGeAlD
Loperamide—Altered state of consciousness—Temozolomide—skin cancer	0.00357	0.0261	CcSEcCtD
Loperamide—Abdominal pain upper—Vismodegib—skin cancer	0.00346	0.0253	CcSEcCtD
Loperamide—POMC—lymphoid tissue—skin cancer	0.00321	0.0232	CbGeAlD
Loperamide—POMC—female reproductive system—skin cancer	0.0031	0.0223	CbGeAlD
Loperamide—CALM2—nerve—skin cancer	0.00298	0.0215	CbGeAlD
Loperamide—CALM1—nerve—skin cancer	0.00297	0.0214	CbGeAlD
Loperamide—Bullous eruption—Docetaxel—skin cancer	0.00277	0.0203	CcSEcCtD
Loperamide—POMC—head—skin cancer	0.00259	0.0187	CbGeAlD
Loperamide—CALM2—endothelium—skin cancer	0.00254	0.0183	CbGeAlD
Loperamide—CALM1—endothelium—skin cancer	0.00253	0.0182	CbGeAlD
Loperamide—CALM2—hair follicle—skin cancer	0.00249	0.018	CbGeAlD
Loperamide—CACNA1A—head—skin cancer	0.00247	0.0178	CbGeAlD
Loperamide—CALM2—blood vessel—skin cancer	0.00234	0.0169	CbGeAlD
Loperamide—CALM1—blood vessel—skin cancer	0.00233	0.0168	CbGeAlD
Loperamide—CALM3—nipple—skin cancer	0.00215	0.0155	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Vemurafenib—skin cancer	0.00211	0.0154	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00193	0.0141	CcSEcCtD
Loperamide—Urinary retention—Imiquimod—skin cancer	0.0019	0.0139	CcSEcCtD
Loperamide—Nervous system disorder—Vismodegib—skin cancer	0.00183	0.0134	CcSEcCtD
Loperamide—Skin disorder—Vismodegib—skin cancer	0.00181	0.0132	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.00179	0.0131	CcSEcCtD
Loperamide—CALM2—nipple—skin cancer	0.00169	0.0122	CbGeAlD
Loperamide—CALM1—nipple—skin cancer	0.00168	0.0121	CbGeAlD
Loperamide—CALM2—neck—skin cancer	0.00167	0.0121	CbGeAlD
Loperamide—CALM1—neck—skin cancer	0.00167	0.012	CbGeAlD
Loperamide—Dyspepsia—Vismodegib—skin cancer	0.00164	0.012	CcSEcCtD
Loperamide—OPRK1—female reproductive system—skin cancer	0.00164	0.0118	CbGeAlD
Loperamide—Gastrointestinal disorder—Vismodegib—skin cancer	0.00161	0.0118	CcSEcCtD
Loperamide—Fatigue—Vismodegib—skin cancer	0.00161	0.0117	CcSEcCtD
Loperamide—Constipation—Vismodegib—skin cancer	0.00159	0.0116	CcSEcCtD
Loperamide—Depressed level of consciousness—Temozolomide—skin cancer	0.00159	0.0116	CcSEcCtD
Loperamide—Ileus—Docetaxel—skin cancer	0.00155	0.0113	CcSEcCtD
Loperamide—Erythema multiforme—Vemurafenib—skin cancer	0.00153	0.0112	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.00153	0.0112	CcSEcCtD
Loperamide—Gastrointestinal pain—Vismodegib—skin cancer	0.00152	0.0111	CcSEcCtD
Loperamide—Abdominal pain—Vismodegib—skin cancer	0.00147	0.0108	CcSEcCtD
Loperamide—OPRD1—head—skin cancer	0.00143	0.0103	CbGeAlD
Loperamide—OPRK1—head—skin cancer	0.00137	0.00987	CbGeAlD
Loperamide—Urinary tract disorder—Imiquimod—skin cancer	0.00136	0.00997	CcSEcCtD
Loperamide—Urethral disorder—Imiquimod—skin cancer	0.00135	0.0099	CcSEcCtD
Loperamide—Asthenia—Vismodegib—skin cancer	0.00134	0.00977	CcSEcCtD
Loperamide—Pruritus—Vismodegib—skin cancer	0.00132	0.00964	CcSEcCtD
Loperamide—Erythema multiforme—Imiquimod—skin cancer	0.00131	0.00955	CcSEcCtD
Loperamide—Diarrhoea—Vismodegib—skin cancer	0.00128	0.00932	CcSEcCtD
Loperamide—CALM3—mammalian vulva—skin cancer	0.00126	0.00907	CbGeAlD
Loperamide—Immune system disorder—Imiquimod—skin cancer	0.00125	0.00912	CcSEcCtD
Loperamide—CALM2—connective tissue—skin cancer	0.0012	0.00865	CbGeAlD
Loperamide—CALM1—connective tissue—skin cancer	0.00119	0.00861	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00119	0.00872	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.00119	0.00871	CcSEcCtD
Loperamide—Vomiting—Vismodegib—skin cancer	0.00118	0.00866	CcSEcCtD
Loperamide—Rash—Vismodegib—skin cancer	0.00117	0.00859	CcSEcCtD
Loperamide—Dermatitis—Vismodegib—skin cancer	0.00117	0.00858	CcSEcCtD
Loperamide—Dermatitis bullous—Fluorouracil—skin cancer	0.00115	0.00843	CcSEcCtD
Loperamide—Anaphylactic shock—Vemurafenib—skin cancer	0.00115	0.00841	CcSEcCtD
Loperamide—CALM2—epithelium—skin cancer	0.00114	0.00821	CbGeAlD
Loperamide—CALM1—epithelium—skin cancer	0.00113	0.00818	CbGeAlD
Loperamide—Nervous system disorder—Vemurafenib—skin cancer	0.00113	0.00825	CcSEcCtD
Loperamide—Skin disorder—Vemurafenib—skin cancer	0.00112	0.00817	CcSEcCtD
Loperamide—Nausea—Vismodegib—skin cancer	0.00111	0.00809	CcSEcCtD
Loperamide—Angioedema—Imiquimod—skin cancer	0.0011	0.00803	CcSEcCtD
Loperamide—CALM2—skin of body—skin cancer	0.00108	0.00781	CbGeAlD
Loperamide—CALM1—skin of body—skin cancer	0.00108	0.00778	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.00108	0.00788	CcSEcCtD
Loperamide—Loss of consciousness—Imiquimod—skin cancer	0.00106	0.00773	CcSEcCtD
Loperamide—Abdominal distension—Temozolomide—skin cancer	0.00104	0.00761	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00102	0.00743	CcSEcCtD
Loperamide—Discomfort—Imiquimod—skin cancer	0.00101	0.0074	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00101	0.00739	CcSEcCtD
Loperamide—Dry mouth—Imiquimod—skin cancer	0.001	0.00732	CcSEcCtD
Loperamide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000994	0.00726	CcSEcCtD
Loperamide—Fatigue—Vemurafenib—skin cancer	0.000993	0.00725	CcSEcCtD
Loperamide—CALM2—mammalian vulva—skin cancer	0.000988	0.00713	CbGeAlD
Loperamide—Constipation—Vemurafenib—skin cancer	0.000984	0.00719	CcSEcCtD
Loperamide—CALM1—mammalian vulva—skin cancer	0.000983	0.00709	CbGeAlD
Loperamide—OPRM1—head—skin cancer	0.000974	0.00702	CbGeAlD
Loperamide—Nervous system disorder—Imiquimod—skin cancer	0.000963	0.00704	CcSEcCtD
Loperamide—Skin disorder—Imiquimod—skin cancer	0.000954	0.00697	CcSEcCtD
Loperamide—ABCB1—blood vessel—skin cancer	0.00093	0.00671	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000915	0.00668	CcSEcCtD
Loperamide—CALM2—lymphoid tissue—skin cancer	0.000877	0.00633	CbGeAlD
Loperamide—CALM1—lymphoid tissue—skin cancer	0.000873	0.0063	CbGeAlD
Loperamide—Somnolence—Imiquimod—skin cancer	0.000873	0.00638	CcSEcCtD
Loperamide—Erythema multiforme—Dactinomycin—skin cancer	0.000866	0.00633	CcSEcCtD
Loperamide—Dyspepsia—Imiquimod—skin cancer	0.000864	0.00632	CcSEcCtD
Loperamide—Hypersensitivity—Vemurafenib—skin cancer	0.000848	0.0062	CcSEcCtD
Loperamide—Gastrointestinal disorder—Imiquimod—skin cancer	0.000848	0.00619	CcSEcCtD
Loperamide—Fatigue—Imiquimod—skin cancer	0.000846	0.00619	CcSEcCtD
Loperamide—CALM2—female reproductive system—skin cancer	0.000846	0.0061	CbGeAlD
Loperamide—CALM1—female reproductive system—skin cancer	0.000842	0.00607	CbGeAlD
Loperamide—Dermatitis bullous—Docetaxel—skin cancer	0.000833	0.00609	CcSEcCtD
Loperamide—Asthenia—Vemurafenib—skin cancer	0.000826	0.00604	CcSEcCtD
Loperamide—Urinary tract disorder—Temozolomide—skin cancer	0.000818	0.00598	CcSEcCtD
Loperamide—Pruritus—Vemurafenib—skin cancer	0.000815	0.00595	CcSEcCtD
Loperamide—Urethral disorder—Temozolomide—skin cancer	0.000812	0.00593	CcSEcCtD
Loperamide—CYP2B6—skin of body—skin cancer	0.000805	0.00581	CbGeAlD
Loperamide—Gastrointestinal pain—Imiquimod—skin cancer	0.000803	0.00587	CcSEcCtD
Loperamide—Diarrhoea—Vemurafenib—skin cancer	0.000788	0.00576	CcSEcCtD
Loperamide—Erythema multiforme—Temozolomide—skin cancer	0.000783	0.00572	CcSEcCtD
Loperamide—Urticaria—Imiquimod—skin cancer	0.00078	0.0057	CcSEcCtD
Loperamide—Abdominal pain—Imiquimod—skin cancer	0.000776	0.00567	CcSEcCtD
Loperamide—Dizziness—Vemurafenib—skin cancer	0.000761	0.00556	CcSEcCtD
Loperamide—Immune system disorder—Temozolomide—skin cancer	0.000748	0.00547	CcSEcCtD
Loperamide—Vomiting—Vemurafenib—skin cancer	0.000732	0.00535	CcSEcCtD
Loperamide—Abdominal pain upper—Docetaxel—skin cancer	0.000727	0.00531	CcSEcCtD
Loperamide—Rash—Vemurafenib—skin cancer	0.000726	0.0053	CcSEcCtD
Loperamide—Dermatitis—Vemurafenib—skin cancer	0.000725	0.0053	CcSEcCtD
Loperamide—Hypersensitivity—Imiquimod—skin cancer	0.000723	0.00529	CcSEcCtD
Loperamide—Headache—Vemurafenib—skin cancer	0.000721	0.00527	CcSEcCtD
Loperamide—Discomfort—Bleomycin—skin cancer	0.000719	0.00525	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000717	0.00524	CcSEcCtD
Loperamide—CALM2—head—skin cancer	0.000707	0.0051	CbGeAlD
Loperamide—Asthenia—Imiquimod—skin cancer	0.000704	0.00515	CcSEcCtD
Loperamide—CALM1—head—skin cancer	0.000704	0.00507	CbGeAlD
Loperamide—CYP2C8—female reproductive system—skin cancer	0.000701	0.00506	CbGeAlD
Loperamide—Anaphylactic shock—Bleomycin—skin cancer	0.000697	0.0051	CcSEcCtD
Loperamide—Pruritus—Imiquimod—skin cancer	0.000695	0.00508	CcSEcCtD
Loperamide—Nausea—Vemurafenib—skin cancer	0.000684	0.005	CcSEcCtD
Loperamide—Diarrhoea—Imiquimod—skin cancer	0.000672	0.00491	CcSEcCtD
Loperamide—Discomfort—Dactinomycin—skin cancer	0.00067	0.0049	CcSEcCtD
Loperamide—Angioedema—Temozolomide—skin cancer	0.000659	0.00481	CcSEcCtD
Loperamide—CYP2B6—lymphoid tissue—skin cancer	0.000652	0.0047	CbGeAlD
Loperamide—Dizziness—Imiquimod—skin cancer	0.000649	0.00474	CcSEcCtD
Loperamide—CALM3—lymph node—skin cancer	0.00063	0.00455	CbGeAlD
Loperamide—CYP2B6—female reproductive system—skin cancer	0.000629	0.00454	CbGeAlD
Loperamide—Vomiting—Imiquimod—skin cancer	0.000624	0.00456	CcSEcCtD
Loperamide—Rash—Imiquimod—skin cancer	0.000619	0.00452	CcSEcCtD
Loperamide—Dermatitis—Imiquimod—skin cancer	0.000618	0.00452	CcSEcCtD
Loperamide—Headache—Imiquimod—skin cancer	0.000615	0.0045	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00061	0.00445	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000608	0.00445	CcSEcCtD
Loperamide—Discomfort—Temozolomide—skin cancer	0.000606	0.00443	CcSEcCtD
Loperamide—Dry mouth—Temozolomide—skin cancer	0.0006	0.00439	CcSEcCtD
Loperamide—Anaphylactic shock—Temozolomide—skin cancer	0.000588	0.0043	CcSEcCtD
Loperamide—Nausea—Imiquimod—skin cancer	0.000583	0.00426	CcSEcCtD
Loperamide—Nervous system disorder—Temozolomide—skin cancer	0.000577	0.00422	CcSEcCtD
Loperamide—Skin disorder—Temozolomide—skin cancer	0.000571	0.00418	CcSEcCtD
Loperamide—Fatigue—Dactinomycin—skin cancer	0.000561	0.0041	CcSEcCtD
Loperamide—Discomfort—Fluorouracil—skin cancer	0.000559	0.00408	CcSEcCtD
Loperamide—Urticaria—Bleomycin—skin cancer	0.000554	0.00405	CcSEcCtD
Loperamide—Urinary tract disorder—Docetaxel—skin cancer	0.000544	0.00397	CcSEcCtD
Loperamide—Anaphylactic shock—Fluorouracil—skin cancer	0.000542	0.00396	CcSEcCtD
Loperamide—Urethral disorder—Docetaxel—skin cancer	0.00054	0.00395	CcSEcCtD
Loperamide—Gastrointestinal pain—Dactinomycin—skin cancer	0.000532	0.00389	CcSEcCtD
Loperamide—Nervous system disorder—Fluorouracil—skin cancer	0.000532	0.00389	CcSEcCtD
Loperamide—CYP2B6—head—skin cancer	0.000525	0.00379	CbGeAlD
Loperamide—Somnolence—Temozolomide—skin cancer	0.000523	0.00382	CcSEcCtD
Loperamide—Erythema multiforme—Docetaxel—skin cancer	0.000521	0.00381	CcSEcCtD
Loperamide—Dyspepsia—Temozolomide—skin cancer	0.000518	0.00379	CcSEcCtD
Loperamide—Abdominal pain—Dactinomycin—skin cancer	0.000514	0.00376	CcSEcCtD
Loperamide—Hypersensitivity—Bleomycin—skin cancer	0.000514	0.00376	CcSEcCtD
Loperamide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000508	0.00371	CcSEcCtD
Loperamide—Fatigue—Temozolomide—skin cancer	0.000507	0.00371	CcSEcCtD
Loperamide—Constipation—Temozolomide—skin cancer	0.000503	0.00368	CcSEcCtD
Loperamide—Asthenia—Bleomycin—skin cancer	0.0005	0.00366	CcSEcCtD
Loperamide—Immune system disorder—Docetaxel—skin cancer	0.000497	0.00364	CcSEcCtD
Loperamide—CALM2—lymph node—skin cancer	0.000495	0.00357	CbGeAlD
Loperamide—Pruritus—Bleomycin—skin cancer	0.000493	0.00361	CcSEcCtD
Loperamide—CALM1—lymph node—skin cancer	0.000493	0.00355	CbGeAlD
Loperamide—Somnolence—Fluorouracil—skin cancer	0.000482	0.00352	CcSEcCtD
Loperamide—Gastrointestinal pain—Temozolomide—skin cancer	0.000481	0.00352	CcSEcCtD
Loperamide—Hypersensitivity—Dactinomycin—skin cancer	0.000479	0.0035	CcSEcCtD
Loperamide—Dyspepsia—Fluorouracil—skin cancer	0.000477	0.00349	CcSEcCtD
Loperamide—CYP3A4—female reproductive system—skin cancer	0.000475	0.00343	CbGeAlD
Loperamide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000468	0.00342	CcSEcCtD
Loperamide—Urticaria—Temozolomide—skin cancer	0.000467	0.00342	CcSEcCtD
Loperamide—CYP2D6—female reproductive system—skin cancer	0.000467	0.00337	CbGeAlD
Loperamide—Asthenia—Dactinomycin—skin cancer	0.000467	0.00341	CcSEcCtD
Loperamide—Abdominal pain—Temozolomide—skin cancer	0.000465	0.0034	CcSEcCtD
Loperamide—ABCB1—epithelium—skin cancer	0.000453	0.00326	CbGeAlD
Loperamide—Diarrhoea—Dactinomycin—skin cancer	0.000445	0.00325	CcSEcCtD
Loperamide—Vomiting—Bleomycin—skin cancer	0.000443	0.00324	CcSEcCtD
Loperamide—Rash—Bleomycin—skin cancer	0.00044	0.00321	CcSEcCtD
Loperamide—Dermatitis—Bleomycin—skin cancer	0.000439	0.00321	CcSEcCtD
Loperamide—Hypersensitivity—Temozolomide—skin cancer	0.000433	0.00317	CcSEcCtD
Loperamide—Urticaria—Fluorouracil—skin cancer	0.000431	0.00315	CcSEcCtD
Loperamide—Asthenia—Temozolomide—skin cancer	0.000422	0.00309	CcSEcCtD
Loperamide—Loss of consciousness—Docetaxel—skin cancer	0.000421	0.00308	CcSEcCtD
Loperamide—Pruritus—Temozolomide—skin cancer	0.000416	0.00304	CcSEcCtD
Loperamide—Nausea—Bleomycin—skin cancer	0.000414	0.00303	CcSEcCtD
Loperamide—Vomiting—Dactinomycin—skin cancer	0.000414	0.00302	CcSEcCtD
Loperamide—Rash—Dactinomycin—skin cancer	0.00041	0.003	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000405	0.00296	CcSEcCtD
Loperamide—Diarrhoea—Temozolomide—skin cancer	0.000403	0.00294	CcSEcCtD
Loperamide—Hypersensitivity—Fluorouracil—skin cancer	0.000399	0.00292	CcSEcCtD
Loperamide—Dry mouth—Docetaxel—skin cancer	0.000399	0.00292	CcSEcCtD
Loperamide—ABCB1—mammalian vulva—skin cancer	0.000393	0.00283	CbGeAlD
Loperamide—Anaphylactic shock—Docetaxel—skin cancer	0.000391	0.00286	CcSEcCtD
Loperamide—CYP2D6—head—skin cancer	0.00039	0.00282	CbGeAlD
Loperamide—Dizziness—Temozolomide—skin cancer	0.000389	0.00284	CcSEcCtD
Loperamide—Nausea—Dactinomycin—skin cancer	0.000386	0.00282	CcSEcCtD
Loperamide—Nervous system disorder—Docetaxel—skin cancer	0.000384	0.0028	CcSEcCtD
Loperamide—Pruritus—Fluorouracil—skin cancer	0.000384	0.0028	CcSEcCtD
Loperamide—Skin disorder—Docetaxel—skin cancer	0.00038	0.00278	CcSEcCtD
Loperamide—Vomiting—Temozolomide—skin cancer	0.000374	0.00273	CcSEcCtD
Loperamide—Rash—Temozolomide—skin cancer	0.000371	0.00271	CcSEcCtD
Loperamide—Diarrhoea—Fluorouracil—skin cancer	0.000371	0.00271	CcSEcCtD
Loperamide—Dermatitis—Temozolomide—skin cancer	0.000371	0.00271	CcSEcCtD
Loperamide—Headache—Temozolomide—skin cancer	0.000369	0.00269	CcSEcCtD
Loperamide—Dizziness—Fluorouracil—skin cancer	0.000358	0.00262	CcSEcCtD
Loperamide—Nausea—Temozolomide—skin cancer	0.000349	0.00255	CcSEcCtD
Loperamide—ABCB1—lymphoid tissue—skin cancer	0.000349	0.00251	CbGeAlD
Loperamide—Somnolence—Docetaxel—skin cancer	0.000348	0.00254	CcSEcCtD
Loperamide—Vomiting—Fluorouracil—skin cancer	0.000345	0.00252	CcSEcCtD
Loperamide—Dyspepsia—Docetaxel—skin cancer	0.000344	0.00252	CcSEcCtD
Loperamide—Rash—Fluorouracil—skin cancer	0.000342	0.0025	CcSEcCtD
Loperamide—Dermatitis—Fluorouracil—skin cancer	0.000341	0.0025	CcSEcCtD
Loperamide—Headache—Fluorouracil—skin cancer	0.00034	0.00248	CcSEcCtD
Loperamide—Gastrointestinal disorder—Docetaxel—skin cancer	0.000338	0.00247	CcSEcCtD
Loperamide—Fatigue—Docetaxel—skin cancer	0.000337	0.00247	CcSEcCtD
Loperamide—ABCB1—female reproductive system—skin cancer	0.000336	0.00242	CbGeAlD
Loperamide—Constipation—Docetaxel—skin cancer	0.000335	0.00245	CcSEcCtD
Loperamide—Nausea—Fluorouracil—skin cancer	0.000322	0.00235	CcSEcCtD
Loperamide—Gastrointestinal pain—Docetaxel—skin cancer	0.00032	0.00234	CcSEcCtD
Loperamide—Abdominal pain—Docetaxel—skin cancer	0.000309	0.00226	CcSEcCtD
Loperamide—Hypersensitivity—Docetaxel—skin cancer	0.000288	0.00211	CcSEcCtD
Loperamide—ABCB1—head—skin cancer	0.000281	0.00203	CbGeAlD
Loperamide—Asthenia—Docetaxel—skin cancer	0.000281	0.00205	CcSEcCtD
Loperamide—Pruritus—Docetaxel—skin cancer	0.000277	0.00202	CcSEcCtD
Loperamide—Diarrhoea—Docetaxel—skin cancer	0.000268	0.00196	CcSEcCtD
Loperamide—Dizziness—Docetaxel—skin cancer	0.000259	0.00189	CcSEcCtD
Loperamide—Vomiting—Docetaxel—skin cancer	0.000249	0.00182	CcSEcCtD
Loperamide—Rash—Docetaxel—skin cancer	0.000247	0.0018	CcSEcCtD
Loperamide—Dermatitis—Docetaxel—skin cancer	0.000246	0.0018	CcSEcCtD
Loperamide—Headache—Docetaxel—skin cancer	0.000245	0.00179	CcSEcCtD
Loperamide—Nausea—Docetaxel—skin cancer	0.000232	0.0017	CcSEcCtD
Loperamide—ABCB1—lymph node—skin cancer	0.000197	0.00142	CbGeAlD
Loperamide—CALM1—Signaling by FGFR in disease—HRAS—skin cancer	3.82e-05	0.00027	CbGpPWpGaD
Loperamide—CALM2—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	3.82e-05	0.00027	CbGpPWpGaD
Loperamide—CALM1—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	3.82e-05	0.00027	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR in disease—HRAS—skin cancer	3.82e-05	0.00027	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR—HRAS—skin cancer	3.78e-05	0.000268	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR—HRAS—skin cancer	3.78e-05	0.000268	CbGpPWpGaD
Loperamide—CALM3—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	3.78e-05	0.000267	CbGpPWpGaD
Loperamide—CALM3—Signaling by FGFR in disease—IL6—skin cancer	3.78e-05	0.000267	CbGpPWpGaD
Loperamide—CALM3—DAP12 interactions—IL6—skin cancer	3.78e-05	0.000267	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR in Cancer—HRAS—skin cancer	3.75e-05	0.000265	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR in Cancer—HRAS—skin cancer	3.75e-05	0.000265	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR—IL6—skin cancer	3.74e-05	0.000265	CbGpPWpGaD
Loperamide—CALM1—Signaling by PDGF—HRAS—skin cancer	3.73e-05	0.000264	CbGpPWpGaD
Loperamide—CALM2—Signaling by PDGF—HRAS—skin cancer	3.73e-05	0.000264	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—KRAS—skin cancer	3.73e-05	0.000264	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR in Cancer—IL6—skin cancer	3.71e-05	0.000263	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SUFU—skin cancer	3.69e-05	0.000261	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SUFU—skin cancer	3.69e-05	0.000261	CbGpPWpGaD
Loperamide—CALM3—Signaling by PDGF—IL6—skin cancer	3.69e-05	0.000261	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—NRAS—skin cancer	3.67e-05	0.00026	CbGpPWpGaD
Loperamide—CALM3—Immune System—FOXO4—skin cancer	3.67e-05	0.00026	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CSPG4—skin cancer	3.66e-05	0.000259	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—IL6—skin cancer	3.65e-05	0.000259	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—IL6—skin cancer	3.65e-05	0.000259	CbGpPWpGaD
Loperamide—CALM2—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	3.65e-05	0.000259	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR in disease—IL6—skin cancer	3.65e-05	0.000259	CbGpPWpGaD
Loperamide—CALM1—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	3.65e-05	0.000259	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR in disease—IL6—skin cancer	3.65e-05	0.000259	CbGpPWpGaD
Loperamide—CALM3—B Cell Activation—HRAS—skin cancer	3.65e-05	0.000258	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR—IL6—skin cancer	3.62e-05	0.000256	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR—IL6—skin cancer	3.62e-05	0.000256	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR in Cancer—IL6—skin cancer	3.59e-05	0.000254	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR in Cancer—IL6—skin cancer	3.59e-05	0.000254	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—ENO2—skin cancer	3.58e-05	0.000253	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—HRAS—skin cancer	3.58e-05	0.000253	CbGpPWpGaD
Loperamide—CALM2—Signaling by PDGF—IL6—skin cancer	3.57e-05	0.000253	CbGpPWpGaD
Loperamide—CALM1—Signaling by PDGF—IL6—skin cancer	3.57e-05	0.000253	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—NRAS—skin cancer	3.55e-05	0.000252	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—NRAS—skin cancer	3.55e-05	0.000252	CbGpPWpGaD
Loperamide—CALM1—Immune System—FOXO4—skin cancer	3.55e-05	0.000251	CbGpPWpGaD
Loperamide—CALM2—Immune System—FOXO4—skin cancer	3.55e-05	0.000251	CbGpPWpGaD
Loperamide—CALM2—B Cell Activation—HRAS—skin cancer	3.53e-05	0.00025	CbGpPWpGaD
Loperamide—CALM1—B Cell Activation—HRAS—skin cancer	3.53e-05	0.00025	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	3.49e-05	0.000247	CbGpPWpGaD
Loperamide—CALM3—Metabolism—ENO2—skin cancer	3.48e-05	0.000247	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—HRAS—skin cancer	3.46e-05	0.000245	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—HRAS—skin cancer	3.46e-05	0.000245	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TERT—skin cancer	3.46e-05	0.000245	CbGpPWpGaD
Loperamide—CALM3—Disease—FOXO4—skin cancer	3.39e-05	0.00024	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	3.38e-05	0.000239	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	3.38e-05	0.000239	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ENO2—skin cancer	3.37e-05	0.000238	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ENO2—skin cancer	3.37e-05	0.000238	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	3.34e-05	0.000237	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—TP53—skin cancer	3.32e-05	0.000235	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.31e-05	0.000234	CbGpPWpGaD
Loperamide—CALM2—Disease—FOXO4—skin cancer	3.28e-05	0.000232	CbGpPWpGaD
Loperamide—CALM1—Disease—FOXO4—skin cancer	3.28e-05	0.000232	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	3.24e-05	0.000229	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	3.24e-05	0.000229	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—HRAS—skin cancer	3.17e-05	0.000224	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—KRAS—skin cancer	3.16e-05	0.000224	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—KRAS—skin cancer	3.06e-05	0.000217	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—KRAS—skin cancer	3.06e-05	0.000217	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—IL6—skin cancer	3.04e-05	0.000215	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TERT—skin cancer	3.03e-05	0.000215	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ENO2—skin cancer	3.03e-05	0.000214	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PLIN2—skin cancer	2.97e-05	0.00021	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.94e-05	0.000208	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SHH—skin cancer	2.91e-05	0.000206	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—NRAS—skin cancer	2.91e-05	0.000206	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—RASA1—skin cancer	2.89e-05	0.000205	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SHH—skin cancer	2.82e-05	0.000199	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SHH—skin cancer	2.82e-05	0.000199	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—RASA1—skin cancer	2.8e-05	0.000198	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—RASA1—skin cancer	2.8e-05	0.000198	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SMO—skin cancer	2.76e-05	0.000195	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTCH1—skin cancer	2.76e-05	0.000195	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—HRAS—skin cancer	2.74e-05	0.000194	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—BRAF—skin cancer	2.74e-05	0.000194	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—HRAS—skin cancer	2.69e-05	0.00019	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTGER4—skin cancer	2.69e-05	0.00019	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTCH1—skin cancer	2.67e-05	0.000189	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTCH1—skin cancer	2.67e-05	0.000189	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SMO—skin cancer	2.67e-05	0.000189	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SMO—skin cancer	2.67e-05	0.000189	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—HRAS—skin cancer	2.65e-05	0.000188	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—HRAS—skin cancer	2.65e-05	0.000188	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ENO2—skin cancer	2.64e-05	0.000187	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—HRAS—skin cancer	2.6e-05	0.000184	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—HRAS—skin cancer	2.6e-05	0.000184	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTGER4—skin cancer	2.6e-05	0.000184	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTGER4—skin cancer	2.6e-05	0.000184	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—IL6—skin cancer	2.57e-05	0.000182	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TERT—skin cancer	2.56e-05	0.000181	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—NRAS—skin cancer	2.55e-05	0.000181	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—KRAS—skin cancer	2.51e-05	0.000177	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—IL6—skin cancer	2.49e-05	0.000176	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—IL6—skin cancer	2.49e-05	0.000176	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ENO2—skin cancer	2.49e-05	0.000176	CbGpPWpGaD
Loperamide—CALM3—Disease—ERCC2—skin cancer	2.42e-05	0.000171	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—BRAF—skin cancer	2.4e-05	0.00017	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CSPG4—skin cancer	2.39e-05	0.000169	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FOXO4—skin cancer	2.37e-05	0.000168	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.37e-05	0.000168	CbGpPWpGaD
Loperamide—CALM2—Disease—ERCC2—skin cancer	2.34e-05	0.000165	CbGpPWpGaD
Loperamide—CALM1—Disease—ERCC2—skin cancer	2.34e-05	0.000165	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—NRAS—skin cancer	2.33e-05	0.000165	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FOXO4—skin cancer	2.3e-05	0.000163	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FOXO4—skin cancer	2.3e-05	0.000163	CbGpPWpGaD
Loperamide—CALM3—Disease—TERT—skin cancer	2.26e-05	0.00016	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—NRAS—skin cancer	2.25e-05	0.000159	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—NRAS—skin cancer	2.25e-05	0.000159	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—KRAS—skin cancer	2.2e-05	0.000156	CbGpPWpGaD
Loperamide—CALM2—Disease—TERT—skin cancer	2.19e-05	0.000155	CbGpPWpGaD
Loperamide—CALM1—Disease—TERT—skin cancer	2.19e-05	0.000155	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—NRAS—skin cancer	2.16e-05	0.000153	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—HRAS—skin cancer	2.13e-05	0.000151	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—NRAS—skin cancer	2.1e-05	0.000148	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—ERCC2—skin cancer	2.08e-05	0.000147	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—IL6—skin cancer	2.04e-05	0.000144	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—BRAF—skin cancer	2.03e-05	0.000144	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—NRAS—skin cancer	2.03e-05	0.000143	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—NRAS—skin cancer	2.03e-05	0.000143	CbGpPWpGaD
Loperamide—CALM3—Metabolism—ERCC2—skin cancer	2.02e-05	0.000143	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—NRAS—skin cancer	2.01e-05	0.000142	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—KRAS—skin cancer	2e-05	0.000142	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ERCC2—skin cancer	1.96e-05	0.000139	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ERCC2—skin cancer	1.96e-05	0.000139	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—NRAS—skin cancer	1.95e-05	0.000138	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—NRAS—skin cancer	1.95e-05	0.000138	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—KRAS—skin cancer	1.94e-05	0.000137	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—KRAS—skin cancer	1.94e-05	0.000137	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—HRAS—skin cancer	1.87e-05	0.000132	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—KRAS—skin cancer	1.86e-05	0.000131	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—KRAS—skin cancer	1.8e-05	0.000128	CbGpPWpGaD
Loperamide—CALM3—Disease—BRAF—skin cancer	1.79e-05	0.000127	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—IL6—skin cancer	1.79e-05	0.000127	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TP53—skin cancer	1.78e-05	0.000126	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ERCC2—skin cancer	1.76e-05	0.000125	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—KRAS—skin cancer	1.74e-05	0.000124	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—KRAS—skin cancer	1.74e-05	0.000124	CbGpPWpGaD
Loperamide—CALM1—Disease—BRAF—skin cancer	1.73e-05	0.000123	CbGpPWpGaD
Loperamide—CALM2—Disease—BRAF—skin cancer	1.73e-05	0.000123	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—KRAS—skin cancer	1.73e-05	0.000123	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TP53—skin cancer	1.72e-05	0.000122	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TP53—skin cancer	1.72e-05	0.000122	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—NRAS—skin cancer	1.72e-05	0.000122	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—HRAS—skin cancer	1.7e-05	0.000121	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—KRAS—skin cancer	1.68e-05	0.000119	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—KRAS—skin cancer	1.68e-05	0.000119	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—HRAS—skin cancer	1.65e-05	0.000117	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—HRAS—skin cancer	1.65e-05	0.000117	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ENO2—skin cancer	1.63e-05	0.000115	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TERT—skin cancer	1.59e-05	0.000112	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—HRAS—skin cancer	1.58e-05	0.000112	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TERT—skin cancer	1.53e-05	0.000109	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TERT—skin cancer	1.53e-05	0.000109	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HRAS—skin cancer	1.53e-05	0.000109	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ERCC2—skin cancer	1.53e-05	0.000109	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL6—skin cancer	1.51e-05	0.000107	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—NRAS—skin cancer	1.51e-05	0.000107	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HRAS—skin cancer	1.48e-05	0.000105	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HRAS—skin cancer	1.48e-05	0.000105	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KRAS—skin cancer	1.48e-05	0.000105	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HRAS—skin cancer	1.47e-05	0.000104	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—IL6—skin cancer	1.47e-05	0.000104	CbGpPWpGaD
Loperamide—CALM3—Disease—PTGS2—skin cancer	1.45e-05	0.000103	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ERCC2—skin cancer	1.44e-05	0.000102	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HRAS—skin cancer	1.42e-05	0.000101	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HRAS—skin cancer	1.42e-05	0.000101	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—IL6—skin cancer	1.42e-05	0.0001	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—IL6—skin cancer	1.42e-05	0.0001	CbGpPWpGaD
Loperamide—CALM2—Disease—PTGS2—skin cancer	1.4e-05	9.92e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTGS2—skin cancer	1.4e-05	9.92e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—NRAS—skin cancer	1.34e-05	9.46e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—skin cancer	1.32e-05	9.31e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KRAS—skin cancer	1.3e-05	9.19e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—NRAS—skin cancer	1.29e-05	9.15e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—NRAS—skin cancer	1.29e-05	9.15e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NRAS—skin cancer	1.27e-05	9.02e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—HRAS—skin cancer	1.26e-05	8.91e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—BRAF—skin cancer	1.26e-05	8.89e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTGS2—skin cancer	1.25e-05	8.82e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—NRAS—skin cancer	1.22e-05	8.64e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—BRAF—skin cancer	1.21e-05	8.6e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—BRAF—skin cancer	1.21e-05	8.6e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—skin cancer	1.21e-05	8.59e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—skin cancer	1.2e-05	8.53e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—NRAS—skin cancer	1.18e-05	8.36e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NRAS—skin cancer	1.18e-05	8.36e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—skin cancer	1.17e-05	8.31e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—skin cancer	1.17e-05	8.31e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—skin cancer	1.15e-05	8.17e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—KRAS—skin cancer	1.15e-05	8.14e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—NRAS—skin cancer	1.13e-05	7.98e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—KRAS—skin cancer	1.11e-05	7.87e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—KRAS—skin cancer	1.11e-05	7.87e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HRAS—skin cancer	1.1e-05	7.81e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KRAS—skin cancer	1.1e-05	7.77e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—NRAS—skin cancer	1.09e-05	7.72e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—NRAS—skin cancer	1.09e-05	7.72e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—skin cancer	1.06e-05	7.48e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—skin cancer	1.06e-05	7.47e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—KRAS—skin cancer	1.05e-05	7.44e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—KRAS—skin cancer	1.02e-05	7.19e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—KRAS—skin cancer	1.02e-05	7.19e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HRAS—skin cancer	9.77e-06	6.92e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—skin cancer	9.75e-06	6.9e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—KRAS—skin cancer	9.7e-06	6.87e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HRAS—skin cancer	9.45e-06	6.69e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HRAS—skin cancer	9.45e-06	6.69e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ERCC2—skin cancer	9.45e-06	6.69e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—KRAS—skin cancer	9.38e-06	6.64e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—KRAS—skin cancer	9.38e-06	6.64e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—skin cancer	9.35e-06	6.62e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HRAS—skin cancer	9.33e-06	6.6e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—skin cancer	9.19e-06	6.51e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—skin cancer	9.05e-06	6.4e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—skin cancer	9.05e-06	6.4e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—HRAS—skin cancer	8.93e-06	6.32e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—skin cancer	8.93e-06	6.32e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—skin cancer	8.66e-06	6.13e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—HRAS—skin cancer	8.64e-06	6.11e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—HRAS—skin cancer	8.64e-06	6.11e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—skin cancer	8.55e-06	6.05e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—skin cancer	8.27e-06	5.85e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—skin cancer	8.27e-06	5.85e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—HRAS—skin cancer	8.24e-06	5.84e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—HRAS—skin cancer	7.97e-06	5.65e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—HRAS—skin cancer	7.97e-06	5.65e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NRAS—skin cancer	7.89e-06	5.59e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—skin cancer	7.89e-06	5.59e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NRAS—skin cancer	7.63e-06	5.4e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NRAS—skin cancer	7.63e-06	5.4e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—skin cancer	7.63e-06	5.4e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—skin cancer	7.63e-06	5.4e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KRAS—skin cancer	6.79e-06	4.81e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KRAS—skin cancer	6.57e-06	4.65e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KRAS—skin cancer	6.57e-06	4.65e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—skin cancer	6.04e-06	4.27e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—skin cancer	5.84e-06	4.13e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—skin cancer	5.84e-06	4.13e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HRAS—skin cancer	5.77e-06	4.09e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—skin cancer	5.66e-06	4.01e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HRAS—skin cancer	5.58e-06	3.95e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HRAS—skin cancer	5.58e-06	3.95e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—skin cancer	5.53e-06	3.91e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—skin cancer	5.35e-06	3.78e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—skin cancer	5.35e-06	3.78e-05	CbGpPWpGaD
